JP2023509212A5 - - Google Patents
Info
- Publication number
- JP2023509212A5 JP2023509212A5 JP2022542256A JP2022542256A JP2023509212A5 JP 2023509212 A5 JP2023509212 A5 JP 2023509212A5 JP 2022542256 A JP2022542256 A JP 2022542256A JP 2022542256 A JP2022542256 A JP 2022542256A JP 2023509212 A5 JP2023509212 A5 JP 2023509212A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010020878 | 2020-01-09 | ||
| CN202010020878.7 | 2020-01-09 | ||
| PCT/CN2021/070832 WO2021139758A1 (zh) | 2020-01-09 | 2021-01-08 | 新型多肽复合物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023509212A JP2023509212A (ja) | 2023-03-07 |
| JP2023509212A5 true JP2023509212A5 (https=) | 2024-01-16 |
| JPWO2021139758A5 JPWO2021139758A5 (https=) | 2024-01-16 |
| JP7773981B2 JP7773981B2 (ja) | 2025-11-20 |
Family
ID=76787741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542256A Active JP7773981B2 (ja) | 2020-01-09 | 2021-01-08 | 新型ポリペプチド複合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230120270A1 (https=) |
| EP (1) | EP4089111A4 (https=) |
| JP (1) | JP7773981B2 (https=) |
| KR (1) | KR20220123072A (https=) |
| CN (1) | CN114746440B (https=) |
| AU (1) | AU2021205561A1 (https=) |
| CA (1) | CA3164979A1 (https=) |
| TW (1) | TWI878430B (https=) |
| WO (1) | WO2021139758A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3981788A4 (en) | 2019-06-04 | 2023-03-22 | Jiangsu Hengrui Medicine Co., Ltd. | ANTIBODY CAPABLE OF BINDING THYMIC STROMAL LYMPHOPOIETIN AND ITS USE |
| MX2023006596A (es) * | 2020-12-03 | 2023-06-19 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Composicion farmaceutica de anticuerpo anti-tslp y uso de la misma. |
| TW202317635A (zh) * | 2021-07-14 | 2023-05-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合ｈｇｆｒ和ｅｇｆｒ的抗原結合分子及其醫藥用途 |
| WO2023147784A1 (zh) | 2022-02-07 | 2023-08-10 | 江苏恒瑞医药股份有限公司 | 特异性结合psma和cd3的抗原结合分子及其医药用途 |
| CN118660910A (zh) | 2022-03-14 | 2024-09-17 | 江苏恒瑞医药股份有限公司 | 特异性结合gprc5d和cd3的抗原结合分子及其医药用途 |
| TW202405015A (zh) * | 2022-04-11 | 2024-02-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合ｐｓｍａ和ｃｄ２８的抗原結合分子及其醫藥用途 |
| TW202413416A (zh) * | 2022-04-11 | 2024-04-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合ｅｇｆｒ和ｃｄ２８的抗原結合分子及其醫藥用途 |
| EP4545564A4 (en) * | 2022-06-23 | 2026-01-14 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Antigen-binding molecule specifically binding to DLL3 and CD3, and its pharmaceutical use |
| TW202413437A (zh) | 2022-08-05 | 2024-04-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合ｇｕｃｙ２ｃ和ｃｄ３的抗原結合分子及其醫藥用途 |
| WO2024131864A1 (zh) * | 2022-12-21 | 2024-06-27 | 广东菲鹏制药股份有限公司 | 一种il-10单体融合蛋白 |
| CN121712807A (zh) | 2023-08-31 | 2026-03-20 | 江苏恒瑞医药股份有限公司 | Ctla4/tigit结合蛋白及其医药用途 |
| WO2025082377A1 (zh) * | 2023-10-17 | 2025-04-24 | 江苏恒瑞医药股份有限公司 | 一种抗tslp抗体的药物组合物及其用途 |
| WO2025106278A1 (en) | 2023-11-17 | 2025-05-22 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5889151A (en) | 1989-10-20 | 1999-03-30 | Societe Leb-Tech | Purified human alpha interferon receptor |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| WO2007062037A2 (en) * | 2005-11-21 | 2007-05-31 | Laboratoires Serono Sa | Compositions and methods of producing hybrid antigen binding molecules and uses thereof |
| AU2006333077A1 (en) | 2005-12-15 | 2007-07-12 | Becton, Dickinson And Company | Diagnosis of sepsis |
| AU2008247649A1 (en) | 2007-05-01 | 2008-11-13 | University Of Miami | Transcriptomic biomarkers for individual risk assessment in new onset heart failure |
| WO2012142159A2 (en) * | 2011-04-11 | 2012-10-18 | The Brigham And Women's Hospital, Inc | Structural mutations in titin cause dilated cardiomyopathy |
| WO2014014796A1 (en) * | 2012-07-18 | 2014-01-23 | Eli Lilly And Company | Multi-specific igg-(fab)2 constructs containing t-cell receptor constant domains |
| CN104619715B (zh) | 2012-09-14 | 2018-06-05 | 弗·哈夫曼-拉罗切有限公司 | 包含至少两个不同实体的分子的生产和选择方法及其用途 |
| ES2936810T3 (es) | 2014-05-16 | 2023-03-22 | Pfizer | Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería |
| CN108601830B (zh) * | 2015-12-18 | 2023-02-03 | 比奥根Ma公司 | 双特异性抗体平台 |
| CN117843810A (zh) | 2017-09-22 | 2024-04-09 | 上海药明生物技术有限公司 | 新型双特异性多肽复合物 |
| CN109970860A (zh) * | 2017-12-27 | 2019-07-05 | 信达生物制药(苏州)有限公司 | 三链抗体、其制备方法及其用途 |
-
2021
- 2021-01-08 CA CA3164979A patent/CA3164979A1/en active Pending
- 2021-01-08 CN CN202180006946.7A patent/CN114746440B/zh active Active
- 2021-01-08 KR KR1020227026346A patent/KR20220123072A/ko active Pending
- 2021-01-08 AU AU2021205561A patent/AU2021205561A1/en active Pending
- 2021-01-08 JP JP2022542256A patent/JP7773981B2/ja active Active
- 2021-01-08 EP EP21738017.9A patent/EP4089111A4/en active Pending
- 2021-01-08 TW TW110100845A patent/TWI878430B/zh active
- 2021-01-08 US US17/791,579 patent/US20230120270A1/en active Pending
- 2021-01-08 WO PCT/CN2021/070832 patent/WO2021139758A1/zh not_active Ceased